Article Details
Retrieved on: 2021-03-09 13:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
BITT is initiating clinical trials for BITR2101, its lead candidate, a monoclonal antibody that targets tumor necrosis factor receptor 2 (TNFR2). BITT is also ...
Article found on: www.galvnews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here